Scarica l'app Stockscreener
3.82
2.30%
0.09
Precedente Chiudi:
$3.91
Aprire:
$3.93
Volume 24 ore:
7,986
Relative Volume:
0.22
Capitalizzazione di mercato:
$6.48M
Reddito:
$2.00M
Utile/perdita netta:
$-59.61M
Rapporto P/E:
-0.1009
EPS:
-37.8642
Flusso di cassa netto:
$-48.20M
1 W Prestazione:
+10.50%
1M Prestazione:
-11.31%
6M Prestazione:
-90.60%
1 anno Prestazione:
-79.02%
Intervallo 1D:
$3.822
$4.09
Intervallo di 1 settimana:
$3.4201
$4.15
Portata 52W:
$3.26
$71.50
Bioatla Inc Stock (BCAB) Company Profile
Nome
Bioatla Inc
Settore
Industria
Telefono
858-558-0708
Indirizzo
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
3.91 | 6.48M | 2.00M | -59.61M | -48.20M | -37.86 |
VRTX
Vertex Pharmaceuticals Inc
|
441.12 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
627.54 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
823.07 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.46 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.97 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-08-13 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-05-05 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-06-28 | Iniziato | ROTH Capital | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | BTIG Research | Buy |
| 2021-01-11 | Iniziato | Credit Suisse | Outperform |
| 2021-01-11 | Iniziato | JP Morgan | Overweight |
| 2021-01-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Bioatla Inc Borsa (BCAB) Ultime notizie
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (BCAB) Q4 2025 Earnings: EPS $-8.00 Beats EstimatesStrong Earnings Momentum - The Legal Advocate
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
Context to pay $6.5M for full CT-202 rights by Aug. 1, 2026 - Stock Titan
The real story behind BioAtla BCAB valuation 333 20260507Community Sell Signals - Newser
BioAtla (BCAB) slashes R&D, flags going-concern risk amid cash crunch - Stock Titan
BioAtla, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Number of shareholders of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla (BCAB) Stock Analysis: +2.61% Gain — What to Watch 2026-05-14Continuation Pattern - newser.com
BCAB Q1'26 Earnings: EPS estimate is (10.00) USD - TradingView
TradingKey - TradingKey
The real story behind BioAtla (BCAB) valuation (-3.33%) 2026-05-07Quote Data - Newser
BCAB BioAtla delivers narrower than expected Q4 2025 loss, shares gain nearly two percent today.Social Trade Signals - newser.com
Why is BioAtla (BCAB) stock gaining attention recently | Q4 2025: Better Than ExpectedMarket Hype Signals - Newser
BioAtla, Inc. Executive Compensation, Governance, and Board Diversity Overview 2025 - Minichart
Executive pay, board and share data detailed in BioAtla (NASDAQ: BCAB) 10-K/A - Stock Titan
Is BioAtla (BCAB) stock reacting to key levels | Q4 2025: Earnings Beat EstimatesQuarterly Financial Update - Newser
BioAtla to implement 50-for-1 share consolidation - MSN
BCAB Stock Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Highs Report: What is the dividend yield of BioAtla IncPortfolio Performance Report & Verified Technical Signals - baoquankhu1.vn
BCAB Q4 2025 Earnings: BioAtla Inc. EPS Beats Estimates With No Revenue - Newser
BCAB Stock Analysis: BioAtla Inc. Biotech Drops 3.12% to $0.13 Key Takeaways - Newser
BioAtla Announces 1-for-50 Reverse Stock Split Merger - TipRanks
[8-K] BioAtla, Inc. Reports Material Event - Stock Titan
Bio files certificate of merger; 50-for-1 reverse stock split effective Apr 6 - TradingView
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
BioAtla To Carry Out 1-for-50 Reverse Stock Split On April 6th, 2026 - Moomoo
BCAB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BioAtla announces 50-for-1 reverse stock split effective April 6 - Investing.com Australia
BioAtla announces 50-for-1 reverse stock split effective April 6 By Investing.com - Investing.com South Africa
BioAtla Begins Strategic Review Following 2025 Results - TipRanks
BioAtla Announces 50-for-1 Share Consolidation - National Today
BioAtla Announces Share Consolidation - Investing News Network
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
BioAtla Q4 net loss narrows on lower expenses - TradingView
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - The Manila Times
BRIEF-BioAtla Q4 Net Income USD -9.784 Million - TradingView
Strategic shake-up at BioAtla (NASDAQ: BCAB) as oncology pipeline and funding plans are reassessed - Stock Titan
BioAtla (NASDAQ: BCAB) posts 2025 loss, launches asset monetization review - Stock Titan
Aug Decliners: How much upside does BioAtla Inc haveCPI Data & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
BioAtla, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Wrap: Will BioAtla Inc stock hit new highs in YEAR2026 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Bioatla Inc Azioni (BCAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.67%
1.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):